David Provence, Ph.D.

Disclaimer: Transmission of information to us via voicemail or this website does not establish an attorney-client relationship. If you are not already a client of Mueting Raasch Group, do not send any information that you would have treated confidentially.

BIOGRAPHY

David is a patent attorney practicing in the life sciences and biotechnology.

David has experience in patent preparation and prosecution in the U.S. Patent and Trademark Office, and in assisting counsel throughout the world to obtain patent protection outside of the United States. David’s practice includes large and small companies and universities.

EDUCATION

  • William Mitchell College of Law
    • J.D.
    • Honors: cum laude
  • Washington University School of Medicine
    • Ph.D., Molecular Microbiology and Microbial Pathogenesis
    • Postdoctoral Research Associate, Development of signal transduction assays in peripheral monocytes and cultured macrophages
  • Lawrence University
    • B.A., Biology
    • Honors: cum laude

BAR ADMISSIONS

  • Minnesota
  • U.S. Patent and Trademark Office

PROFESSIONAL ASSOCIATIONS

  • American Society for Microbiology
  • American Association for the Advancement of Science
  • Association of University Technology Managers
  • American Intellectual Property Law Association
  • Minnesota Intellectual Property Law Association

PUBLICATIONS & PRESENTATIONS

  • “Anticipating Inherency Issues: To Recognize Or Not To Recognize . . . But . . . Where Does Enablement Fit In?” presented at Advanced Patent Practice CLE sponsored by the Minnesota State Bar Association, Minneapolis, Minnesota, February 2004.
  • “From Lab to Market: The Challenges of Bringing Research to the Public Through Technology Commercialization,” presented at the College of Veterinary Medicine, University of Minnesota, November 2, 2007.
  • “Globalization and Implications for Technology Transfer,” Moderator, presented at The Association of University Technology Managers Central Regional Meeting, Cleveland, Ohio, July 2008.
  • “Patent Law Primer,” presented at The Association of University Technology Managers Central Regional Meeting, Madison, Wisconsin, July 2009.
  • “Managing Legal Costs: Patent Strategies That Stretch Your Legal Budget,” presented at The Association of University Technology Managers Central Regional Meeting, Memphis, Tennessee, July 2010.
  • “A Brief Introduction to Patenting Biotech: The Times They Are A-Changin’,” presented at the 2010 BioTechnology Institute Retreat, University of Minnesota, October 6, 2010.
  • “Commercial Influence on Academic Research and the University Mission,” Moderator, presented at The Association of University Technology Managers Central Regional Meeting, Louisville, Kentucky, July 2011.
  • File Format Fiasco: Filing Patent Applications in DOCX,” presented at the Patent Prosecution Section Roundtable, Minnesota Intellectual Property Law Association, Minneapolis, Minnesota, January 12, 2023.
  • Provence, D.L., A. Olsen, and R. Curtiss III, “Preliminary analysis of hemagglutination and fibronectin binding by avian pathogenic Escherichia coli,” Abstract, Gordon Conference on Microbial Toxins and Pathogenesis (1991).
  • Provence, D.L., and R. Curtiss III, “Role of crl in avian pathogenic Escherichia coli: a knockout mutation of crl does not affect hemagglutination activity, fibronectin binding, or curli production,” Infection and Immunity, 60, 4460-4467 (1992).
  • Provence, D.L., “Mannose-resistant hemagglutination and fibronectin binding by avian pathogenic Escherichia coli,” Abstract, 92nd Annual Meeting of the American Society for Microbiology (1992).
  • Provence, D.L., and R. Curtiss III, “Gene transfer in gram-negative bacteria,” In P.Gerhardt (ed.), Methods for General and Molecular Bacteriology pp. 317-347, American Society for Microbiology, Washington D.C. (1993).
  • Provence, D.L., and R. Curtiss III, “The genetic and molecular basis of hemagglutination by an avian pathogenic Escherichia coli: the putative hemagglutinin has significant homology to the Hemophilus influenzae and Neisseria gonnorrhoeae IgA1 proteinases,” Abstract, Gordon Conference on Molecular Mechanisms of Microbial Adhesion (1993).
  • Provence, D.L., and R. Curtiss III. “Isolation and characterization of a gene involved in hemagglutination by an avian pathogenic Escherichia coli,” Infection and Immunity, 62, 1369-1380 (1994).
  • Provence, D.L., and R. Curtiss III. “Secretion of an Escherichia coli protein: similarities to the autosecretory proteins of Hemophilus influenzae and Neisseria gonnorrhoeae,” Abstract, Gordon Conference on Microbial Toxins and Pathogenesis (1994).
  • Stathopoulos C., D.L. Provence, and R. Curtiss III. “Characterization of the avian pathogenic Escherichia coli hemagglutinin Tsh, a member of the immunoglobulin A protease-type family of autotransporters,” Infection and Immunity, 67, 772-781 (1994).

TECHNOLOGIES

  • Agricultural biotechnology
  • Biomedical sciences
  • Biotechnology
  • Genetics
  • Glycobiology
  • Microbiology
  • Structural and functional genomics
  • Transgenic plants

SERVICES

  • Patent Preparation and Prosecution – Domestic/International
  • Patent Portfolio Management
  • Strategic Counseling